ACTRIMS 2022 | Metformin – a means to promote remyelination in the ageing MS population?

Jason Plemel, PhD, University of Alberta, Edmonton, AB, Canada, talks about an exciting avenue of research conducted out of the Cambridge group – metformin, as a means for remyelination. This drug appears to act on oligodendrocytes to promote a more rejuvenated biology – inducing them to act like younger cells rather than the actual aged scenario. Having been tested in animal models, remyelination has been promoted in both young and old animals – inferring promising results for future clinical trials. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.